Hofseth BioCare Past Earnings Performance

Past criteria checks 0/6

Hofseth BioCare's earnings have been declining at an average annual rate of -8.7%, while the Biotechs industry saw earnings growing at 15.7% annually. Revenues have been growing at an average rate of 26.7% per year.

Key information

-8.7%

Earnings growth rate

-1.7%

EPS growth rate

Biotechs Industry Growth	20.9%
Revenue growth rate	26.7%
Return on equity	-259.3%
Net Margin	-48.8%
Next Earnings Update	16 May 2024

Recent past performance updates

Recent updates

Hofseth BioCare (OB:HBC) Shareholders Have Enjoyed A Whopping 339% Share Price Gain

Nov 20

Revenue & Expenses Breakdown
Beta

How Hofseth BioCare makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OB:HBC Revenue, expenses and earnings (NOK Millions)
Date	Revenue	Earnings	G+A Expenses
31 Dec 23	219	-107	76
30 Sep 23	205	-93	78
30 Jun 23	185	-105	77
31 Mar 23	134	-140	76
31 Dec 22	120	-137	76
30 Sep 22	113	-136	66
30 Jun 22	96	-139	64
31 Mar 22	102	-135	63
31 Dec 21	88	-126	60
30 Sep 21	85	-120	44
30 Jun 21	79	-115	47
31 Mar 21	68	-111	45
31 Dec 20	69	-102	43
30 Sep 20	57	-104	46
30 Jun 20	79	-90	37
31 Mar 20	72	-86	36
31 Dec 19	68	-89	34
30 Sep 19	71	-79	41
30 Jun 19	59	-81	42
31 Mar 19	61	-83	42
31 Dec 18	61	-85	43
30 Sep 18	73	-74	36
30 Jun 18	84	-66	36
31 Mar 18	75	-66	36
31 Dec 17	66	-16	34
30 Sep 17	43	-28	27
30 Jun 17	19	-60	24
31 Mar 17	21	-92	21
31 Dec 16	20	-147	21
30 Sep 16	21	-165	26
30 Jun 16	34	-137	28
31 Mar 16	32	-109	28
31 Dec 15	32	-100	27
30 Sep 15	38	-84	22
30 Jun 15	23	-82	22
31 Mar 15	24	-72	22
31 Dec 14	20	-67	22
30 Sep 14	39	-40	27
30 Jun 14	62	-35	30
31 Mar 14	63	-39	30
31 Dec 13	63	-52	31
30 Sep 13	41	-98	31
30 Jun 13	27	-96	26

Quality Earnings: HBC is currently unprofitable.

Growing Profit Margin: HBC is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: HBC is unprofitable, and losses have increased over the past 5 years at a rate of 8.7% per year.

Accelerating Growth: Unable to compare HBC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HBC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).

Return on Equity

High ROE: HBC has a negative Return on Equity (-259.32%), as it is currently unprofitable.

Hofseth BioCare Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Full year 2023 earnings released: kr0.27 loss per share (vs kr0.37 loss in FY 2022)

Full year 2023 earnings released: kr0.27 loss per share (vs kr0.37 loss in FY 2022)

Hofseth BioCare ASA to Report Q4, 2024 Results on Feb 14, 2025

Third quarter 2023 earnings released: kr0.06 loss per share (vs kr0.09 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: kr0.015 (vs kr0.079 loss in 2Q 2022)

First quarter 2023 earnings released: kr0.10 loss per share (vs kr0.10 loss in 1Q 2022)

Recent updates

Full year 2023 earnings released: kr0.27 loss per share (vs kr0.37 loss in FY 2022)

New minor risk - Share price stability

Hofseth BioCare ASA Announces Board Changes

New major risk - Financial position

Full year 2023 earnings released: kr0.27 loss per share (vs kr0.37 loss in FY 2022)

Hofseth BioCare ASA to Report Q4, 2024 Results on Feb 14, 2025

Third quarter 2023 earnings released: kr0.06 loss per share (vs kr0.09 loss in 3Q 2022)

New minor risk - Market cap size

Second quarter 2023 earnings released: EPS: kr0.015 (vs kr0.079 loss in 2Q 2022)

CFO & COO recently bought kr200k worth of stock

New minor risk - Market cap size

Hofseth Biocare ASA Announces the Online Publication of Its Abstract

First quarter 2023 earnings released: kr0.10 loss per share (vs kr0.10 loss in 1Q 2022)

Here's Why Hofseth BioCare (OB:HBC) Can Afford Some Debt

Chief Scientific Officer recently bought kr538k worth of stock

Independent Director recently bought kr272k worth of stock

Full year 2022 earnings released: kr0.37 loss per share (vs kr0.35 loss in FY 2021)

We Think Hofseth BioCare (OB:HBC) Has A Fair Chunk Of Debt

Hofseth BioCare ASA to Report Fiscal Year 2022 Results on Mar 31, 2023

Third quarter 2022 earnings released: kr0.09 loss per share (vs kr0.11 loss in 3Q 2021)

Third quarter 2022 earnings released: kr0.09 loss per share (vs kr0.11 loss in 3Q 2021)

Hofseth BioCare ASA's Progo Bioactive Peptides Now Is A "New Dietary Ingredient" for the US FDA

Second quarter 2022 earnings released: kr0.08 loss per share (vs kr0.069 loss in 2Q 2021)

Hofseth BioCare ASA Announces Executive Changes

Chief Executive Officer recently bought kr170k worth of stock

First quarter 2022 earnings released: kr0.10 loss per share (vs kr0.075 loss in 1Q 2021)

Health Check: How Prudently Does Hofseth BioCare (OB:HBC) Use Debt?

Full year 2021 earnings released: kr0.35 loss per share (vs kr0.31 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Chief Executive Officer recently bought kr367k worth of stock

Hofseth Biocare ASA Successfully Receive New Dietary Ingredient (NDI) Status from the US FDA

Third quarter 2021 earnings released: kr0.11 loss per share (vs kr0.10 loss in 3Q 2020)

Hofseth BioCare (OB:HBC) Is Carrying A Fair Bit Of Debt

Chief Commercial Officer recently bought kr200k worth of stock

Chief Executive Officer recently bought kr361k worth of stock

Second quarter 2021 earnings released: kr0.07 loss per share (vs kr0.062 loss in 2Q 2020)

Hofseth BioCare ASA Provides Earnings Guidance for the Second Half of 2021 and Next Year 2022

Independent Director recently bought kr385k worth of stock

First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.055 loss in 1Q 2020)

Full year 2020 earnings released: kr0.31 loss per share (vs kr0.29 loss in FY 2019)

Is Hofseth BioCare (OB:HBC) Using Debt Sensibly?

Full year 2020 earnings released: kr0.31 loss per share (vs kr0.29 loss in FY 2019)

How Much Of Hofseth BioCare ASA (OB:HBC) Do Insiders Own?

Chief Executive Officer recently bought kr505k worth of stock

Chief Executive Officer recently bought kr505k worth of stock

Chief Executive Officer recently bought kr505k worth of stock

New 90-day high: kr9.80

Are Insiders Buying Hofseth BioCare ASA (OB:HBC) Stock?

Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 39.999995 million.

Hofseth Biocare ASA and Tenet Partners Initiate A Long-Term Collaboration to Build A Global Brand and Launch HBC Own Branded Consumer Health Products

Hofseth BioCare ASA and DKSH Announces A Pan-Asian Exclusive Collaboration for Distribution of HBC Branded Products Including Across China, India, Japan & Korea

Hofseth Biocare Asa Signs Exclusive Distribution Agreement with Leading Speciality Chemicals and Ingredients Distributor IMCD

Hofseth Biocare ASA Hires Andy Gill as VP from January 2021

Hofseth BioCare ASA, Annual General Meeting, Apr 23, 2021

Hofseth BioCare (OB:HBC) Shareholders Have Enjoyed A Whopping 339% Share Price Gain

Hofseth Biocare ASA Approves Appointment of Christoph Baldegger as New Member of the Audit Committee

Third quarter earnings released

New 90-day low: kr7.98

HBC Receives Approval from Health Canada for Qualified Health Claims Focused on Maintaining Healthy Levels of Ferritin and Hemoglobin and the Blood Components Required for Oxygen Transport

Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 200 million.

Hofseth Biocare ASA's Progo’s Bioactive Peptides to Support Healthy Iron Levels to Be Launched in the US

Hofseth BioCare ASA Announces the First Part of its Accelerated Phase 2 Trial of Cardio™ Soft Gels for the Treatment of Patients with COVID-19

New 90-day low - kr8.16

First half earnings released

Hofseth BioCare ASA (OB:HBC) acquired a 34% stake in Atlantic Delights Ltd. for $0.7 million.

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Revenue & Expenses Breakdown
Beta